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OBJECTIVES: The objective of this study was to estimate the
direct annual cost of treating patients with schizophrenia in
Greece, in 2005. METHODS: Due to the lack of quantitative
data, information on the treatment pathway and medical
resource utilization of patients were collected from a consensus
panel of 9 psychiatrists representing different medical settings
and geographic regions and 5 health economists. For estimating
costs a bottom up approach from the National Health System
perspective was used. Cost analysis included personnel salaries,
diagnostic procedures, medication, outpatient visits, hospitaliza-
tion and stay in supervised dwelling. Due to the variations
between hospital pricing and reimbursement, three-scenarios
were used to account for variability on hospitalization costs.
RESULTS: The panel of experts deﬁned three patient categories
based on the severity of the disease and the medical setting where
treatment is received: (a) outpatient setting (50% probability of
hospitalization for 20 days per year); (b) ambulatory care (100%
probability of hospitalization for 50 days per year); and (c) inpa-
tient setting (100% probability of hospitalization for 60 days per
year and 40% probability of 305-day stay in protected dwelling).
The annual direct cost of treatment per patient was found to be:
€3187 (€2659–€4166) in the ﬁrst category, €10,135 (€7429–
€13,972) in the second category and €20,782 (€17,482–€25,462)
in the third category. The total cost of treatment increased with
the severity of the disease and the use of hospitalization, while
the contribution of medication to the total cost decreased com-
pared to other cost attributes. CONCLUSIONS: The provision
of health care to schizophrenic patients has a high cost for the
health care system. Systematic data collection on medical
resource utilization must be established at the national level to
facilitate further research and guide the efﬁcient use of resources.
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OBJECTIVES: This analysis estimated the cost-utility of second-
line treatment for major depressive disorder using generic selec-
tive serotonin reuptake inhibitors (SSRIs), escitalopram,
paroxetine CR, sertraline or venlafaxine XR. METHODS: A
Markov probabilistic decision analysis was constructed with
cycle dependent transition probabilities for persistency over 52
weeks, examining whether persistent patients would have a
response, and if this response was followed by remission.
Response was °Y´50% improvement from baseline in depression
rating score. Remission was deﬁned as °Ü7 HAM-D or °Ü10
MADRS. Remission and response rates were obtained from pub-
lished clinical trials and entered into the model using beta dis-
tributions. Utilities were based on duration of treatment and
changed weekly over the year. Baseline utility scores were 0.35,
0.21, and 0.30 for remission, response, and treatment failure,
respectively; between days 56–365 utility scores were 0.85, 0.72,
and 0.58, respectively. Wholesale acquisition costs were used for
medication costs. Remission, response, and treatment failure
costs were obtained from the literature and were estimated using
gamma distributions. The analysis was conducted using 10,000
Monte Carlo simulations with ﬁrst- and second-order sampling
procedures. RESULTS: The lowest cost option was generic SSRI
agents ($3283), with the highest being venlafaxine XR ($4111).
The effectiveness was greatest for venlafaxine XR (35.2 quality-
adjusted life weeks (QALWs), followed by escitalopram (34.1),
sertraline (34.1), generic SSRIs (33.8), and paroxetine CR (33.4).
Cost per QALW ranged from $97 for generic SSRIs to $117 for
venlafaxine XR. The incremental cost effectiveness ratio (ICER)
for venlafaxine XR relative to generic SSRIs was $609. When
QALW are converted to quality-adjusted life years (QALYs), the
ICER per QALY for venlafaxine XR relative to generic SSRIs
was $31,621. CONCLUSIONS: Using a Monte Carlo Markov
model, the analysis suggests that venlafaxine XR is more effec-
tive in terms of QALWs and has an acceptable ICER relative to
generic SSRIs.
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The major cost to the health care system in treating schizophre-
nia is hospital based care. To help estimate the cost of treating
schizophrenia and to assess the effectiveness of treatment com-
prehensive data on rehospitalization rates are appropriate.
OBJECTIVE: To conduct a systematic review of the literature on
rehospitalization rates for schizophrenia. METHODS: Published
clinical trials of antipsychotic medications and large representa-
tive naturalistic studies were systematically identiﬁed by con-
ducting searches of the Cochrane Library Schizophrenia Group’s
Register and MEDLINE databases. Identiﬁed sources were sup-
plemented with a reference search for additional relevant litera-
ture. Studies were included if they were published from
1990–2004 and reported 1-year rehospitalization rates among
patients not hospitalized. This included (a) clinical trials of out-
patients or of recent discharge patients; and (b) naturalistic
cohorts followed after discharge from hospital. Hospitalization
rates were adjusted based on the sample size. Studies were strat-
iﬁed based on the patient group treated. RESULTS: Patients after
their ﬁrst hospitalization for schizophrenia (ﬁrst episode patients;
n = 36,192) from case registries in 5 nations had an average
annual readmission rate of 33% (range 15–55%). Of stable
response patients, comparison between patients on ﬁrst genera-
tion (conventional; n = 265) and second generation (novel; n =
628) antipsychotic regimes indicated that those on second gen-
eration were signiﬁcantly less likely to be readmitted (Mean dif-
ference = 3.02; 95% CI = 1.75:4.29). Similarly, of patients
treated for clinical exacerbation comparison between patients on
ﬁrst (n = 761) and second generation (n = 1141) regimes indi-
cated that those on a second generation regime were signiﬁcantly
less likely to be readmitted (Mean difference = 5.07; 95% CI =
4.41:5.72). CONCLUSIONS: Rehospitalization rates were sig-
niﬁcantly lower for patients on second than ﬁrst generation
antipsychotics. This ﬁnding appears to be robust across patient
groupings. The use of second generation antipsychotics may
reduce the cost of care.
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Violent crimes perpetrated by the mentally ill are a global
problem causing signiﬁcant ﬁnancial and human burden. Severe
mental disorders are associated with an increased risk of violent
offending. However, predicting violent offending in the mentally
